AFP and hepatocellular carcinoma: In a phase I trial, Nakagawa et al. explored an AFP peptide vaccine for advanced hepatocellular carcinoma (HCC), observing an immune response in five patients, one of whom achieved complete remission (CR) and eight others maintained stable disease (SD) without serious AEs [27].